REQUEST A DEMO
Total
USD $0.00
Search more companies

Uni-Bio Science Group Limited (Hong Kong SAR, China)

Main Activities: Pharmaceutical and Medicine Manufacturing
Full name: Uni-Bio Science Group Limited Profile Updated: June 14, 2024
Buy our report for this company USD 29.95 Most recent financial data: 2023 Available in: English & Chinese Download a sample report

Uni-Bio Science Group Limited (HKEX: 0690) is a leading Chinese biopharmaceutical and healthcare company focused on four strategic areas: innovative drugs, high-value generic drugs, medical aesthetics raw materials, and CMO services. The company was established in 2001 and has a long history of operation. With a senior management team that possesses decades of international pharmaceutical industry experience and unique expertise in the Chinese healthcare sector, Uni-Bio Science Group is well-positioned to benefit from the positive changes in the Chinese medical market. The company is dedicated to improving patients' quality of life through innovative therapies and meeting China's demand for high-quality healthcare solutions. The aging population, population growth, and various chronic diseases in China have put significant pressure on the domestic healthcare system. However, Uni-Bio Science Group has established a strong presence and is equipped to address this challenge with its diverse product portfolio and experienced commercial team, achieving several significant milestones. The company has been actively enhancing its operational capabilities to sustain its strong growth momentum. Measures implemented include the establishment of medical and market access departments and increasing market activities to gain market share. Uni-Bio Science Group has achieved excellent results in expanding its product portfolio through strategic partnerships and licensing agreements. Recently, the company formed a strategic alliance with Hong Kong Group, one of the top 50 private enterprises in China. The collaboration includes promoting Uni-Bio Science Group's products through Hong Kong Group's healthcare channels. This alliance further demonstrates the company's broad commercial and research and development expertise, as well as its commitment to ethical and responsible business practices, making it a renowned player in the field of healthcare and a preferred partner for many institutions. The company's innovative business model enables it to maintain competitiveness and develop world-class treatment and healthcare solutions for the benefit of patients nationwide. Uni-Bio Science Group has made and will continue to invest in ensuring supply chain security and accountability, in line with the latest policies and guidelines introduced by the Chinese government. All of the company's production facilities nationwide are equipped with state-of-the-art equipment and have obtained cGMP certification, making Uni-Bio Science Group a high-quality pharmaceutical supplier. With its solid foundation and outstanding achievements in the focused treatment field, Uni-Bio Science Group will continue to strive to become a leader in chronic disease management, providing innovative health products and treatment solutions for China.

Headquarters
Unit 502, 5th Floor, No. 20 Science Park East Avenue, Hong Kong Science Park, Shatin, New Territories, Hong Kong
Hong Kong; Hong Kong;

Contact Details: Purchase the Uni-Bio Science Group Limited report to view the information.

Website: http://www.uni-bioscience.com

Basic Information
Total Employees:
Purchase the Uni-Bio Science Group Limited report to view the information.
Outstanding Shares:
Purchase the Uni-Bio Science Group Limited report to view the information.
Registered Capital:
Purchase the Uni-Bio Science Group Limited report to view the information.
Financial Auditors:
Purchase the Uni-Bio Science Group Limited report to view the information.
Incorporation Date:
February 20, 2001
Key Executives
Purchase this report to view the information.
Chairman
Purchase this report to view the information.
Vice Chairman
Purchase this report to view the information.
Director/Member of the Board
Purchase this report to view the information.
Director/Member of the Board
Purchase this report to view the information.
Outside Director
Ownership Details
Purchase this report to view the information.
25.94%
Purchase this report to view the information.
13.59%
Purchase this report to view the information.
10.33%
Subsidiaries
Beijing Genetech Pharmaceutical Co., Limited (China)
100%
Beijing Taili Kechuan Bioengineering Co., Ltd. (China)
100%
Lelion Holding Limited
100%
Company Performance
Financial values in the chart are available after Uni-Bio Science Group Limited report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency HKD. Absolute financial data is included in the purchased report.
Net sales revenue
9.48%
Total operating revenue
8.77%
Operating profit (EBIT)
63.86%
EBITDA
64.82%
Net Profit (Loss) for the Period
71.02%
Total assets
56.48%
Total equity
39.11%
Operating Profit Margin (ROS)
8.71%
Net Profit Margin
8.87%
Return on Equity (ROE)
4.02%
Debt to Equity Ratio
20.33%
Quick Ratio
0.13%
Cash Ratio
0.11%

To view more information, Request a demonstration of the EMIS service

Buy this company report
Need ongoing access to company, industry or country information?